10.03.25 -- End-To-End Support For Biologic API And Drug Product Development

Discover how advanced mRNA manufacturing innovations, including optimized RNA synthesis and scalable LNP encapsulation, are accelerating therapeutic development.

Our experience and capabilities foster a collaborative environment, enabling us to develop and implement innovative analytical methods that efficiently address the testing needs of our partners.

Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

We bring over two decades of cell line development (CLD) experience together with state-of-the-art technologies to ensure every step is strategically designed and meticulously executed.

Our capabilities span cell and protein sciences, high-throughput screening, assay development, biomarker validation, radiometric assays, DMPK, animal pharmacology, and exploratory toxicology.

Learn how this transient platform accelerates biologics production, seamlessly transitioning from discovery to stable CHO-K1, ensuring scalability, and reducing risks in manufacturing.

Utilizing robust analytical services at every stage of development and manufacturing is crucial to ensure your therapy reaches patients in need on time and within budget.

Backed by a history of success, including 29 mammalian-derived market products, as your one-stop partner, we offer fast and tailored transfers for your unique needs.

With decades of experience, we’ve helped develop multiple particle engineering-based drug delivery platforms and supported the commercialization of many enhanced drug products.

With multiple cGMP manufacturing lines, a flexible uni-flow design, and cutting-edge single-use technologies, our Seattle campus is touted as one of the most productive CDMO facilities in the nation.

Join 1,000+ pharma, biotech, and drug delivery professionals at the PODD: Partnership Opportunities in Drug Delivery Conference conference, October 27–28 in Boston. Featuring 10 technology tracks, pharma company spotlights, 1:1 partnering, and more. Attendees will also hear from leaders at companies including AbbVie, Amgen, AstraZeneca, Biogen, Eli Lilly, GSK, Moderna, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and others. Register at PODDConference.com with code LSL20 for 20% off.

This 11-12 November, Cell 2025 unites 1,000+ experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development. Gain insights across cell culture, therapy development, and CGT manufacturing, and learn from world-renowned leaders Bobby Gaspar (Orchard Therapeutics), Christof Von Kalle, (Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now